MX2022000990A - Composiciones y metodos que se dirigen y eliminan celulas madre cancerosas (csc) positivas para alfa-v beta-3 (av?3) y tratan canceres resistentes a farmacos y metastasicos. - Google Patents

Composiciones y metodos que se dirigen y eliminan celulas madre cancerosas (csc) positivas para alfa-v beta-3 (av?3) y tratan canceres resistentes a farmacos y metastasicos.

Info

Publication number
MX2022000990A
MX2022000990A MX2022000990A MX2022000990A MX2022000990A MX 2022000990 A MX2022000990 A MX 2022000990A MX 2022000990 A MX2022000990 A MX 2022000990A MX 2022000990 A MX2022000990 A MX 2022000990A MX 2022000990 A MX2022000990 A MX 2022000990A
Authority
MX
Mexico
Prior art keywords
cancer
drug resistant
compositions
killing
methods
Prior art date
Application number
MX2022000990A
Other languages
English (en)
Inventor
David Cheresh
Hiromi Wettersten
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of MX2022000990A publication Critical patent/MX2022000990A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2848—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

En modalidades alternativas, se proporcionan composiciones y métodos para tratar o aliviar un cáncer avanzado tal como un cáncer resistente a fármacos o metastásico el cual expresa polipéptidos avß3 en su superficie celular, o para eliminar células madre cancerosas (CSC) las cuales expresan polipéptidos avß3 en su superficie celular, utilizando anticuerpos humanos o humanizados capaces de unirse específicamente a los polipéptidos avß3 (avb3) expresados en la superficie celular cuya región Fc tiene una afinidad selectiva por el Fc?Rl (CD64) humano, pero no por otros FcR, en células efectoras tales como macrófagos, neutrófilos, y células dendríticas. Al administrar estos anticuerpos a un individuo que los necesita, estos anticuerpos humanos o humanizados son capaces de tratar, aliviar o ralentizar el desarrollo del cáncer avanzado o cáncer resistente a fármacos, o un cáncer causado o iniciado por o mantenido por un cáncer avanzado o célula cancerosa resistente a fármacos o una célula madre cancerosa (CSC).
MX2022000990A 2019-08-02 2020-07-31 Composiciones y metodos que se dirigen y eliminan celulas madre cancerosas (csc) positivas para alfa-v beta-3 (av?3) y tratan canceres resistentes a farmacos y metastasicos. MX2022000990A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962882296P 2019-08-02 2019-08-02
PCT/US2020/044596 WO2021026024A1 (en) 2019-08-02 2020-07-31 Compositions and methods for targeting and killing alpha-v beta-3 -positive cancer stem cells (cscs) and treating drug resistant and metastatic cancers

Publications (1)

Publication Number Publication Date
MX2022000990A true MX2022000990A (es) 2022-02-16

Family

ID=74259051

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022000990A MX2022000990A (es) 2019-08-02 2020-07-31 Composiciones y metodos que se dirigen y eliminan celulas madre cancerosas (csc) positivas para alfa-v beta-3 (av?3) y tratan canceres resistentes a farmacos y metastasicos.

Country Status (11)

Country Link
US (1) US20210032348A1 (es)
EP (1) EP4007579A4 (es)
JP (1) JP2022543199A (es)
KR (1) KR20220041111A (es)
CN (1) CN114144181A (es)
AU (1) AU2020324391A1 (es)
BR (1) BR112022001273A2 (es)
CA (1) CA3144473A1 (es)
IL (1) IL289476A (es)
MX (1) MX2022000990A (es)
WO (1) WO2021026024A1 (es)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5753230A (en) * 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
US7659374B2 (en) * 2004-08-16 2010-02-09 Medimmune, Llc Eph receptor Fc variants with enhanced antibody dependent cell-mediated cytotoxicity activity
BRPI0706540A2 (pt) * 2006-01-18 2011-03-29 Merck Patent Gmbh terapia especìfica usando ligantes de integrina para tratar cáncer
EP2714738B1 (en) * 2011-05-24 2018-10-10 Zyngenia, Inc. Multivalent and monovalent multispecific complexes and their uses
WO2016100858A1 (en) * 2014-12-18 2016-06-23 The Regents Of The University Of California Methods for inhibiting alpha-v beta-3 expression on cancer stem cells and inhibiting progression to a cancer stem cell phenotype
EP3323826A1 (en) * 2016-11-21 2018-05-23 Danmarks Tekniske Universitet Native chinese hamster ovary cell secretion signal peptides for production of recombinant polypeptides
WO2018183894A1 (en) * 2017-03-31 2018-10-04 The Regents Of The University Of California Compositions and methods for targeting and killing alpha-v beta-3-positive cancer stem cells (cscs) and treating drug resistant cancers
JP7285936B2 (ja) * 2019-01-22 2023-06-02 ブリストル－マイヤーズ スクイブ カンパニー Ｉｌ－７ｒアルファサブユニットに対する抗体及びその使用

Also Published As

Publication number Publication date
JP2022543199A (ja) 2022-10-11
IL289476A (en) 2022-02-01
US20210032348A1 (en) 2021-02-04
EP4007579A1 (en) 2022-06-08
AU2020324391A1 (en) 2022-01-20
CA3144473A1 (en) 2021-02-11
EP4007579A4 (en) 2023-08-09
CN114144181A (zh) 2022-03-04
KR20220041111A (ko) 2022-03-31
WO2021026024A1 (en) 2021-02-11
BR112022001273A2 (pt) 2022-06-07

Similar Documents

Publication Publication Date Title
PH12020551160A1 (en) Chimeric antigen receptors targeting cd70
ZA202007393B (en) Diverse antigen binding domains, novel platforms and other enhancements for cellular therapy
EP4353318A3 (en) Compositions and methods for targeting and killing alpha-v beta-3-positive cancer stem cells (cscs) and treating drug resistant cancers
MX2019008503A (es) Receptores de antigenos quimericos contra axl o ror2 y metodos de uso de los mismos.
MX2022006444A (es) Linfocitos t activados por bite ex vivo.
MY189113A (en) Eribulin-based antibody-drug conjugates and methods of use
WO2018236870A3 (en) METHODS AND COMPOSITIONS FOR TARGETING CANCER CELLS WITH A CHIMERIC ANTIGENIC RECEPTOR
MX346973B (es) Anticuerpos especificos de tumores y usos para los mismos.
MX2021014094A (es) Conjugados de anticuerpo-farmaco inhibidores de mcl-1 y sus metodos de uso.
MX2017003246A (es) Macropinocitosis de anticuerpos anti-cd46 humanos y agentes terapeuticos dirigidos contra el cancer.
MX2017014716A (es) Polipeptido de fusion anti-cancer.
TN2012000437A1 (en) Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
AU2015219495B2 (en) Disease therapy by inducing immune response to Trop-2 expressing cells
PH12015502112A1 (en) Cancer treatment using antibodies that bind cell surface grp78
RU2014138038A (ru) Фармацевтическая композиция для лечения профилактики рака
WO2003105758A3 (en) CANCER-RELATED GENE USED AS A TARGET FOR CHEMOTHERAPY
WO2003104399A3 (en) CANCER-RELATED GENE AS A TARGET IN CHEMOTHERAPY
MX2020005640A (es) Anticuerpos anti-liv1 humanizados para el tratamiento de cancer de mama.
MX2018014863A (es) Régimen de dosificación para proteína de fusión de tcr especifico de gp100 - scfv anti - cd3.
MX2021002225A (es) Composiciones y metodos para la reprogramacion de tcr mediante el uso de proteinas de fusion.
EA201691053A1 (ru) Соединения к рецептору фактора роста фибробластов 3 типа (fgfr3) и способы терапии
WO2017177217A3 (en) Chimeric receptors and uses thereof in immune therapy
ZA202206323B (en) Treatment involving immune effector cells genetically modified to express antigen receptors
WO2011119888A3 (en) N-cadherin: target for cancer diagnosis and therapy
WO2019100052A3 (en) Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof